Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma

NCT06279767 is registered in ClinicalTrials.gov with The First Affiliated Hospital with Nanjing Medical University as lead sponsor.

NCT NCT06279767
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06279767 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of TMZ Plus 6-MP in the Patients With Recurrent Glioblastoma
Lead sponsor
The First Affiliated Hospital with Nanjing Medical University
Phase
Phase 1/2
Overall status
Unknown status
Start date
July 1, 2022
Completion date
July 31, 2025
Enrollment
27 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, glioblastoma, temozolomide